Locations:
December 9, 2025/Cancer/News & Insight

Novel Community Campaign Increases Venous Thromboembolism Awareness

National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour

church bus tour

Black Americans have a significantly higher incidence, severity and mortality from venous thromboembolism (VTE) compared to other racial and ethnic groups. Despite this elevated risk, awareness and education about VTE remain limited in many Black communities.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

To address this knowledge gap, the National Blood Clot Alliance launched the Black Lives Advocating for Clot Knowledge (B.L.A.C.K) Church Bus Tour, which partnered with faith-based institutions in southeastern Black communities. This program aimed to empower individuals to recognize VTE risk factors and symptoms, know when to seek prompt care and learn about preventive actions.

A bold approach

Featuring a bright-red bus with signage describing VTE symptoms, the campaign educated individuals to take steps to reduce the risk of VTE and to recognize the condition when it occurs. The bus tour included four churches in Charlotte, NC, Marietta, GA and Memphis, TN. The tour incorporated educational sessions and the distribution of educational materials.

Researchers collected pre- and post-event surveys to assess changes in knowledge resulting from the program. The findings were presented at the 2025 ASH annual meeting.

“The NBCA bus tour campaign underscores the value of culturally tailored educational interventions in addressing gaps in VTE awareness,” says Dana Angelini, MD, a physician in the Classical Hematology team at Cleveland Clinic Cancer Institute.

Program demographics

More than 450 people participated in the events across the southeastern U.S. The majority of participants were between 61-70 years old, and 73.1% were female. Most participants identified as Black, non-Hispanic.

Roughly 89% participants said they had not personally experienced a blood clot and they did not have a friend or family member who had experienced one.

Advertisement

Increasing awareness

Wilcoxon signed-rank test was used to compare section and total survey scores before and after the program. Analysis of the pre- and post-surveys found a statistically significant increase in awareness across 16 knowledge domains. In addition to gaining knowledge about symptoms and treatments, the overwhelming majority of participants also strongly agreed to make lifestyle changes to reduce their risk of contracting VTE.

Additionally, most participants reported their intention to share this knowledge in the community. “This finding demonstrates the power that community education has to spread awareness to those who are in front of us and beyond,” says Dr. Angelini.

What’s next

Based on the success of the program, the National Blood Clot Alliance is working on a “2.0” version of the bus tour, and hopes to make this an annual endeavor. The plan is to continue to raise awareness in the hopes of fostering earlier intervention and risk mitigation and ultimately reduce VTE-associated mortality rates. “This initiative highlights the importance of meeting people where they are, in environments where they feel comfortable, and providing them with trusted health education.,” says Dr. Angelini.

Advertisement

Related Articles

Patient and doctor
October 9, 2026/Cancer/News & Insight

First Radioligand Therapy Approved for Metastatic Hormone-Sensitive Prostate Cancer

Adding 177Lu-PSMA-617 to ADT plus an ARPI cut the risk of radiographic progression or mortality by 28%

Woman running
October 7, 2026/Cancer/Patient Support

Pilot Project Aids Cancer Survivors in Achieving Healthy Weight and Reducing Recurrent Risk

New program will help patients improve fitness and manage weight after cancer treatment

Dr Keith McCrae
October 6, 2026/Cancer/Benign Hematology

How is ITP Therapy Evolving?

Cleveland Clinic hematologist highlights new guidelines and treatment advances in immune thrombocytopenia

Bone metastasis
October 5, 2026/Cancer/Innovations

Digital Platform Cuts Bone Metastasis Treatment Decision Time

NIMBLE replaces weekly tumor board delays with same-day multidisciplinary recommendations

Prostate cancer
October 2, 2026/Cancer/Radiation Oncology

ArteraAI Prostate Biomarker Accurate Across Diverse Populations

Cleveland Clinic study provides validation for the test, which combines AI and pathological data to predict outcomes in postoperative patients

Prostate cancer illustration
October 1, 2026/Cancer/Radiation Oncology

PSMA PET Scan-Guided LDR Brachytherapy Can Control Localized Prostate Cancer Recurrence

Advanced imaging technology catches metastases much earlier, allowing treatment with fewer side effects

Throat cancer
September 30, 2026/Cancer/Radiation Oncology

Same Cure Rate, Less Radiation in HPV-Associated Oral Cancer

Reduced radiation for lymph node areas reduces side effects

Lung cancer illustration
September 29, 2026/Cancer/Radiation Oncology

Single-Fraction SBRT Shows Comparable Outcomes to Three-Fraction Approach in Early-Stage Lung Cancer

Large Cleveland Clinic analysis may help resolve a longstanding question over optimal fractionation

Ad